HongCRES Group

The Guangdong-Hong Kong-Macao Greater Bay Area, with its vast population and leading economic strength, is fully committed to developing its pharmaceutical industry.

Leveraging its traditional advantages as an international city in Asia, Hong Kong has been a global leader in biomedical innovations, boasting strong capabilities in both basic and clinical research. In the area of clinical trial management, Hong Kong has built a long-established international clinical trial capabilities, experience, networks, and accreditation. By integrating clinical trial institutions within the Greater Bay Area and across the country, the initiative endeavors to enhance national clinical trial capabilities, strengthen the international biopharmaceutical supply chain, and expand its international influence.

With extensive experience, The University of Hong Kong Clinical Trials Centre (HKU-CTC) has offered a cutting-edge one-stop international clinical trial professional management model. To achieve this goal, HKU-CTC has been authorized by The University of Hong Kong to establish the HONGCRES® Group, comprising HKU Clinical Research Limited. and its Shenzhen-based subsidiary “HKU Clinical Research (Shenzhen) , to promote and develop the innovative ClinCluster® international clinical trial institution management network in the Greater Bay Area, forming a strategic alliance with clinical trial institutions in the region, aiming to develop the Greater Bay Area into a world-class hub for clinical trial development, drug development, and research.

The HONGCRES® Group is led by current HKU-CTC senior executives, all of whom were core members directly involved in the design and development of the ClinCluster® model for many years and possess extensive experience in clinical trial management and operations.